Navigation Links
ImQuest Presentation at Keystone Symposium Focuses on Advancements in Their Cancer Research and Development Program
Date:4/8/2009

FREDERICK, Md., April 8 /PRNewswire/ -- ImQuest Life Sciences presented their latest biological results supporting the continued development of their novel small molecule piperazine compound for the treatment of solid tumors at the Targeted Cancer Therapeutics meeting held in Whistler, British Columbia. The presentation highlighted advances in the development of ImQuest's lead microtubule inhibitor, IQP-0304. The piperazines demonstrate potent antiproliferative activity against a variety of tumor cell types (prostate, lung, ovary, colon, CNS, melanoma, and hematopoietic lineages) by disruption of cell cycle progression and induction of apoptosis with a secondary anti-angiogenic activity as a consequence of the cytoskeletal disruption. The unique activity, novel structure, potent in vivo efficacy in murine xenograft models, as well as a favorable toxicity profile, potential for oral bioavailability and straight-forward cGMP manufacturing suggest that IQP-0304 might be an important addition to the currently available therapeutic regimens used to treat solid tissue malignancies. Dr. Nick Kaludov, Ph.D., Director of Scientific Operations, presented the new findings which also included toxicology and toxicokinetic evaluations.

"These results highlight the significant potential of the piperazines as highly potent and broadly active chemotherapeutic agents and provide additional rationale for their expedited development," said Dr. Robert W. Buckheit Executive Vice President and Chief Scientific Officer, and presentation co-author.

ImQuest Life Sciences, a privately held U.S. company located in Frederick, Maryland specializes in the preclinical and clinical development of novel compounds for the treatment of infectious disease and cancer. ImQuest BioSciences, also located in Frederick, Maryland, is a leading provider of anti-infective and anti-cancer drug and vaccine development services to the biotechnology and pharmaceutical industry.

    For further information regarding this press release please contact:
    Robert W. Buckheit, Jr., Ph.D.
    Executive Vice President and Chief Scientific Officer
    ImQuest Life Sciences, Inc.
    301-696-0274
    rbuckheit@imquest.com


'/>"/>
SOURCE ImQuest Life Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. ImQuest Presents Data on the Anti-Hepatitis B Virus Activity of Pyrimidinediones at the 13th ISVHLD Meeting in Washington D.C.
2. ImQuest Presentations at CROI Report Significant Advances in Therapeutic and Microbicide Product Development Programs
3. ImQuest Presents IND-Enabling Safety Pharmacology and Pharmacokinetic Data for the Therapeutic HIV Compound IQP-0410 at Conference on Retroviruses and Opportunistic Infections
4. ImQuest Receives $6.4 M Five Year Award from NIH to Develop Long-Lasting Combination Topical Microbicides To Prevent HIV Transmission
5. ImQuest Awarded SBIR Grant to Define the Mechanism of Action of Their Lead Anti-HIV Therapeutic Compound IQP-0410
6. Frost & Sullivan Hosts Presentation on MicroRNAs: From Stem Cells and Cancer to Diagnostics and Therapeutics
7. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Citi Conference
8. Encision Enters Into Sales Representation Agreement With Caldera Medical
9. Spectral announces presentations at the 29TH International Symposium on Intensive Care and Emergency Medicine focusing on the role of endotoxin
10. Cytopia Scientific Presentation on JAK2 Inhibitor Program at American Chemical Society Conference
11. Alexzas Corporate Presentation to be Webcast at the Future Leaders in the Biotech Industry Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)...  The Biodesign Challenge (BDC), a university competition that ... living systems and biotechnology, announced its winning teams at ... New York City . The teams, ... at MoMA,s Celeste Bartos Theater during the daylong summit. ... curator of architecture and design, and Suzanne Lee ...
(Date:6/23/2016)... June 23, 2016 Apellis Pharmaceuticals, Inc. ... clinical trials of its complement C3 inhibitor, APL-2. ... multiple ascending dose studies designed to assess the ... subcutaneous injection in healthy adult volunteers. ... as a single dose (ranging from 45 to ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... and technical consulting, provides a free webinar on Performing Quality Investigations: ... 2016 at 12pm CT at no charge. , Incomplete investigations are still a ...
Breaking Biology Technology:
(Date:5/16/2016)... YORK , May 16, 2016   EyeLock ... solutions, today announced the opening of an IoT Center ... to strengthen and expand the development of embedded iris ... an unprecedented level of convenience and security with unmatched ... authenticate one,s identity aside from DNA. EyeLock,s platform uses ...
(Date:5/9/2016)... UAE, May 9, 2016 Elevay ... comes to expanding freedom for high net worth professionals ... in today,s globally connected world, there is still no ... could ever duplicate sealing your deal with a firm ... passports by taking advantage of citizenship via investment programs ...
(Date:4/28/2016)... and BANGALORE, India , April 28, 2016 ... a product subsidiary of Infosys (NYSE: INFY ), ... a global partnership that will provide end customers ... mobile banking and payment services.      (Logo: ... innovation area for financial services, but it also plays a ...
Breaking Biology News(10 mins):